Zhejiang Jingxin Pharmaceutical Co., Ltd. (SHE: 002020)

Zhejiang Jingxin Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	459.58	1,461	1,548	1,561	915.35	493.22
Short-Term Investments	-	-	-	-	70.21	90.26
Trading Asset Securities	811.85	150.96	366.89	422.4	1,179	1,948
Cash & Short-Term Investments	1,271	1,612	1,915	1,983	2,164	2,532
Cash Growth	-25.70%	-15.85%	-3.41%	-8.38%	-14.51%	20.50%
Accounts Receivable	743.01	612.58	509.57	510.67	379.93	479.12
Other Receivables	70.06	51.44	59.13	103.81	53.36	38.01
Receivables	813.06	664.02	568.7	614.47	433.29	517.14
Inventory	699.52	652.69	773.7	677.69	500.76	416.41
Prepaid Expenses	0.43	3.7	2.52	0.81	2.23	0.36
Other Current Assets	206.93	421.56	20.88	17.82	24.35	19.38
Total Current Assets	2,991	3,354	3,281	3,294	3,125	3,485
Property, Plant & Equipment	2,317	2,300	1,632	1,297	1,079	962.42
Long-Term Investments	1,937	1,124	1,134	882.21	681.06	446.43
Goodwill	348.48	348.48	348.48	348.48	257.89	257.89
Other Intangible Assets	392.35	401.26	418.59	157	150.77	166.57
Long-Term Deferred Tax Assets	87.6	80.98	75.11	68.64	43.97	48.57
Long-Term Deferred Charges	41.12	21.2	26.71	55.95	74.03	34.28
Other Long-Term Assets	347.2	356.72	446.73	443.95	254.71	223.76
Total Assets	8,463	7,987	7,363	6,547	5,666	5,625
Accounts Payable	1,066	941.16	719.12	449.79	369.05	456.56
Accrued Expenses	167.12	206.39	187.72	189.47	181.44	142.19
Short-Term Debt	462	279.09	238.58	148.33	300.13	358.5
Current Portion of Long-Term Debt	-	-	0.05	0.27	-	-
Current Portion of Leases	10.96	11.86	14.69	14.66	-	-
Current Income Taxes Payable	51.28	44.3	59.99	50.25	56.06	55.01
Current Unearned Revenue	29.21	53.35	81.01	47.61	48.14	-
Other Current Liabilities	624.65	538.61	514.23	521.88	592.04	758.03
Total Current Liabilities	2,411	2,075	1,815	1,422	1,547	1,770
Long-Term Debt	-	-	-	0.04	0.65	0.9
Long-Term Leases	20.05	31.23	42.98	30.62	-	-
Long-Term Unearned Revenue	267.07	268.81	270.6	128.73	138.7	122.3
Long-Term Deferred Tax Liabilities	76.19	68.4	59.68	65.44	46.55	20.14
Other Long-Term Liabilities	3.2	3.2	1.94	0.74	0.82	0.74
Total Liabilities	2,778	2,446	2,191	1,648	1,734	1,914
Common Stock	861.03	861.03	861.03	905.32	705.51	724.87
Additional Paid-In Capital	1,723	1,723	1,720	2,236	1,897	2,079
Retained Earnings	3,058	2,914	2,554	2,150	1,766	1,345
Treasury Stock	-	-	-	-437.62	-458.13	-458.13
Comprensive Income & Other	14.24	13.86	11.31	8.05	6.37	4.99
Total Common Equity	5,657	5,512	5,146	4,862	3,918	3,696
Minority Interest	28.78	27.78	25.85	37.72	15.07	14.63
Shareholders' Equity	5,685	5,540	5,172	4,899	3,933	3,711
Total Liabilities & Equity	8,463	7,987	7,363	6,547	5,666	5,625
Total Debt	493	322.18	296.3	193.92	300.77	359.4
Net Cash (Debt)	778.43	1,290	1,619	1,789	1,864	2,172
Net Cash Growth	-40.22%	-20.35%	-9.51%	-4.00%	-14.22%	11.63%
Net Cash Per Share	0.90	1.50	1.88	2.19	2.34	2.54
Filing Date Shares Outstanding	861.03	861.03	861.03	861.03	807.73	941.14
Total Common Shares Outstanding	861.03	861.03	861.03	861.03	807.73	941.14
Working Capital	580.3	1,279	1,466	1,872	1,578	1,715
Book Value Per Share	6.57	6.40	5.98	5.65	4.85	3.93
Tangible Book Value	4,916	4,763	4,379	4,356	3,509	3,272
Tangible Book Value Per Share	5.71	5.53	5.09	5.06	4.34	3.48
Buildings	1,629	1,387	934.82	889.16	752.75	740.58
Machinery	1,753	1,412	1,219	946.45	803.63	696.32
Construction In Progress	40.33	482.06	284.91	161.34	139.84	54.3

Source: S&P Capital IQ. Standard template. Financial Sources.